|
Mechanismμ opioid receptor antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date16 Sep 2014 |
United States Post-Marketing Observational Cardiovascular Safety Study in Patients Taking Naloxegol
The overall research goal for this study is to provide additional data to characterize the safety of naloxegol in patients aged 18 years and older who do not have a diagnosis of cancer and who are treated with opioids chronically
100 Clinical Results associated with VALINOR PHARMA, LLC
0 Patents (Medical) associated with VALINOR PHARMA, LLC
100 Deals associated with VALINOR PHARMA, LLC
100 Translational Medicine associated with VALINOR PHARMA, LLC